

Highlights from EBMT 2025: preventing and managing GvHD, harnessing AI in transplant, & more
Apr 17, 2025
Join Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital in Paris, as he dives into the latest advancements in preventing and managing graft-versus-host disease (GvHD). Learn about innovative therapies like Belumazidil and the complexities of CMV and HHV-6 infections after stem cell transplants. The discussion also highlights the potential of artificial intelligence in hematology, advocating for its role as a supportive tool for clinicians while ensuring compassionate patient care. It's a deep dive into the future of hematologic treatment!
AI Snips
Chapters
Transcript
Episode notes
Advances in GvHD Treatment
- Post-transplant cyclophosphamide and ATG combinations reduce graft-versus-host disease incidence effectively.
- New treatments like fecal microbiota and Belumosidil show promise, improving outcomes and safety in resistant GVHD cases.
PTCY Outperforms ATG in GVHD Prevention
- Post-transplant cyclophosphamide (PTCY) excels over ATG in reducing severe acute and chronic GVHD, especially in unrelated donor transplants.
- Combining lower doses of PTCY and ATG may enhance efficacy and reduce toxicity, pending further trials.
Progress in CMV Management
- CMV remains an important transplant complication but is better controlled than decades ago.
- New ECIL guidelines advance diagnosis, prevention, and treatment, with Letermovir soon approved for pediatric use in the EU.